Aster DM Quality Care invests Rs 600+ crore in technology

Aster DM Quality Care invested over Rs 600 crore in medical technology in the 18 months through September 30, 2026, and added eight equipment assets in Q2 FY27, as it expanded complex-care capacity through oncology, robotics, cardiac and imaging systems. The company also launched three specialty centres during the quarter.

What medical technology has Aster DM Quality Care added?

Aster DM Quality Care had 44 catheterisation laboratories, 13 linear accelerator radiotherapy systems, 32 magnetic resonance imaging machines, 33 robots and seven positron emission tomography-computed tomography, or PET-CT, systems as of September 30, 2026. Management said medical-technology investment exceeded Rs 600 crore over the preceding 18 months, without providing a category-wise allocation of that spending.

Aster DM Quality Care listed technology spanning surgical, oncology, cardiac, imaging and neurosciences services. The portfolio includes Da Vinci Xi and SSI Mantra surgical robots, a ROSA brain robot, joint-replacement robots, intraoperative electron radiotherapy, a three-dimensional navigation system for lung-nodule biopsy, biplane catheterisation laboratories, 3T magnetic resonance imaging and Brainlab navigation and robotic imaging systems.

The technology investment formed part of more than Rs 1,200 crore of project, growth and refresh capital expenditure disclosed for the past 18 months. That wider capital-expenditure figure covers more than medical technology alone, so the presentation does not establish how much of the total was assigned to new equipment, hospital projects or replacement spending.

How did Aster DM Quality Care deploy technology in Q2 FY27?

Aster DM Quality Care added one linear accelerator, one digital PET-CT system, three robots, two catheterisation laboratories and one magnetic resonance imaging machine in Q2 FY27. The eight additions were placed across CARE Raipur, CARE Banjara, MIMS Kannur, CARE Bhubaneswar, MIMS Areekode and Aster CMI rather than at a single location.

CARE Raipur received the linear accelerator, digital PET-CT and one robot. CARE Banjara and MIMS Kannur received the other two robots, while CARE Bhubaneswar and MIMS Areekode received one catheterisation laboratory each and Aster CMI received the magnetic resonance imaging machine. These additions were made within a network with 10,840 capacity beds across 27 cities as of September 30, 2026, including 76% of beds in non-metro markets.

Aster DM Quality Care reported growth in several high-end procedures in its CONGO business during Q2 FY27: robotic surgeries rose 39% year on year, kidney transplants rose 31% and joint replacements rose 29%. CONGO revenue increased 16% year on year and accounted for 53% of overall revenue, although the presentation does not quantify revenue generated by individual equipment additions.

The source identifies clinical mechanisms for several assets, including radiation delivery designed to spare healthy tissue through linear accelerators and earlier cancer detection and treatment tracking through digital PET-CT. It does not disclose utilisation rates, procedure counts by machine, or capital returns for the Rs 600 crore-plus technology investment as of September 30, 2026.

Which specialist centres did Aster DM Quality Care launch?

Aster DM Quality Care launched three selected centres of excellence within existing hospitals in Q2 FY27: the ARISE Robotic Spine Institute at Aster CMI in July 2026, the CARE Cancer Institute at Ramkrishna CARE Raipur in August 2026, and the Fetal Medicine Centre of Excellence at Aster Medcity in September 2026. Management described the programme as a way to broaden specialist services and support coordinated care at established hospitals.

The CARE Cancer Institute was commissioned as a 32-bed facility with PET-CT, radiotherapy and bone marrow transplant services. Aster DM Quality Care said the Raipur centre is intended to coordinate diagnosis and treatment closer to patients in Chhattisgarh, while the presentation does not state its occupancy, revenue or procedure targets.

ARISE combines robotic spine care with research and surgeon training, with the intended contribution of expanding precise, minimally invasive spine surgery within neurosciences. The fetal medicine centre provides advanced fetal care and access support through the Jananeyam initiative. The three launches therefore address spine conditions, oncology, and maternal-fetal care, rather than representing an expansion into a single specialty.

Aster DM Quality Care also said all of its hospitals in India are accredited by the National Accreditation Board for Hospitals & Healthcare Providers, or NABH. In Q2 FY27, CARE HITEC City received Joint Commission International accreditation, while Aster MIMS Kasaragod received NABH accreditation within one year of commencing operations.

What clinical activity supports Aster DM Quality Care’s complex-care strategy?

Aster DM Quality Care reported several clinical firsts, including India’s first NanoKnife surgery using irreversible electroporation by the urology team at Aster Medcity, Kochi, and India’s first two-way ABO-incompatible paediatric kidney exchange at Aster CMI. The latter procedure was intended to overcome blood-group barriers in living-donor transplantation.

The company also reported Kerala’s first uniportal robotic-assisted thoracoscopic surgery at Aster MIMS Calicut and Kerala’s first liquid-nitrogen cryoablation for breast fibroadenomas at Aster Medcity. Aster CMI’s clinical team enabled CARE Banjara to perform its first adaptive deep brain stimulation procedure for Parkinson’s disease management using real-time neural-signal-responsive stimulation.

At other units, Aster MIMS Kasaragod performed the district’s first mechanical thrombectomy, while KIMSHEALTH Nagercoil launched a deceased-donor transplant programme and a comprehensive stroke unit. KIMSHEALTH Trivandrum launched a Da Vinci robotic surgery programme that had reached 72 cases. These developments show the strategy being deployed through both technology installation and specialist-programme sharing across hospitals.

On a trailing-12-month and pro-forma basis, Aster DM Quality Care reported more than 97,310 cardiac procedures, 16,845 neuro procedures, 5,130 robotic surgeries, 9,865 joint procedures and 975 transplants. The figures provide network-level clinical scale, but the presentation does not give comparable prior-period procedure counts for each category other than the Q2 FY27 growth rates for robotic surgery, kidney transplants and joint replacements.

How did complex care coincide with Aster DM Quality Care’s Q2 FY27 performance?

Aster DM Quality Care reported revenue of Rs 2,829 crore in Q2 FY27, up 19% from Rs 2,382 crore in Q2 FY26, as total patient volumes rose 12% to 2.18 million. Operational beds increased 4% to 10,611, while occupancy rose 335 basis points to 68% from 65%; average length of stay was unchanged at 3.3 days.

Operating earnings before interest, tax, depreciation and amortisation, or EBITDA, rose 25% to Rs 678 crore from Rs 545 crore. The operating EBITDA margin increased 111 basis points to 24.0% from 22.9%. Management attributed the change to operating leverage in material and other operating costs, higher patient footfall, complex procedures and a favourable payor mix.

The first-half comparison shows a different pace between hospital groups. Mature units accounted for 64% of operational beds, 73% of revenue and 83% of operating EBITDA, with revenue up 18% year on year. Emerging hospitals accounted for 10% of beds and 6% of revenue, but revenue rose 62%, led by the ramp-up of Kasaragod and Nagercoil.

Aster DM Quality Care added a net 66 doctors during Q2 FY27, which management said contributed about Rs 5 crore of monthly revenue. The company also reported return on capital employed of 23.0%, up 152 basis points year on year, using its stated calculation based on EBITDA and average capital employed.

Conclusion

The disclosures link Aster DM Quality Care’s Rs 600 crore-plus medical-technology investment with a broader complex-care model that combines equipment, clinical expertise and specialist centres. In Q2 FY27, revenue growth of 19%, a 39% increase in robotic surgeries and a 16% rise in CONGO revenue coincided with additions across oncology, robotic surgery, cardiac care and imaging.

The next operating evidence will be the ramp-up of the 32-bed CARE Cancer Institute in Raipur and the July-to-September 2026 launches of ARISE and the fetal medicine centre. Management has also identified Kasaragod and Nagercoil as drivers of the emerging-hospital group’s 62% first-half revenue growth, but it has not disclosed unit-level financial or utilisation targets for the new centres and equipment.